 |
|
|
| |
NIS4 for detection of active NASH (NAS≥4)
and significant fibrosis (F≥2) in 714 patients at risk of NASH:
Diagnostic Metrics Are Not Affected By Age, Gender,
Type 2 Diabetes or Obesity
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Dr. Arun J. Sanyal1, Dr. Remy Hanf2, Dr. Stephen A. Harrison3, Dr. Pierre Bedossa4, Prof. Quentin M. Anstee5, Prof. Vlad Ratziu6, Prof. Sven M. Francque7, Dr. Zouher Majd2, Mr. Fouad Ben Sudrick2, Mrs. Emilie Praca2, Mr. John Brozek2, Prof. Bart Staels8, Dr. Sophie Megnien9, Dr. Dean Hum2, Mr. Suneil Hosmane2 and Mr. Pierre Chaumat2, (1)Virginia Commonwealth University, Virginia, USA, (2)Genfit, (3)Pinnacle Clinical Research Center, San Antonio, TX, USA, (4)Pathology, Hopital Beaujon, Clichy, France, (5)Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK, (6)Hopital Pitie-Salpetriere and Sorbonne Universite, (7)Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium, (8)Inserm U1011, (9)Genfit SA
|
| |
|
|
|
|
|
